Mackman Nigel
Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, NC 27599-7035, USA.
Anesth Analg. 2009 May;108(5):1447-52. doi: 10.1213/ane.0b013e31819bceb1.
Tissue factor (TF) is a transmembrane receptor for Factor VII/VIIa (FVII/VIIa). It is constitutively expressed by cells surrounding blood vessels. The endothelium physically separates this potent "activator" from its circulating ligand FVII/FVIIa and prevents inappropriate activation of the clotting cascade. Breakage of the endothelial barrier leads to exposure of extravascular TF and rapid activation of the clotting cascade. TF is also expressed in certain tissues, such as the heart and brain, and provides additional hemostatic protection to these tissues. Small amounts of TF are also present in blood in the form of microparticles, which are small membrane vesicles derived from activated and apoptotic cells. Levels of microparticle TF increase in a variety of diseases, such as sepsis and cancer, and this so-called "blood-borne" TF may contribute to thrombosis associated with these diseases. Recombinant FVIIa has been developed as an effective hemostatic drug for the treatment of hemophilia patients with inhibitory antibodies. In addition, it is used for patients with bleeding that do not respond to conventional therapy. However, the mechanism by which recombinant FVIIa restores hemostasis has not been clearly defined. In conclusion, the TF:FVIIa complex is essential for hemostasis and recombinant FVIIa is an effective hemostatic drug.
组织因子(TF)是因子VII/VIIa(FVII/VIIa)的跨膜受体。它由血管周围的细胞组成性表达。内皮将这种强效的“激活剂”与其循环配体FVII/FVIIa物理分隔开,防止凝血级联反应的不适当激活。内皮屏障的破坏导致血管外TF暴露和凝血级联反应的快速激活。TF也在某些组织中表达,如心脏和大脑,并为这些组织提供额外的止血保护。血液中还存在少量以微粒形式存在的TF,微粒是源自活化和凋亡细胞的小膜泡。在多种疾病中,如脓毒症和癌症,微粒TF水平会升高,这种所谓的“血源性”TF可能促成与这些疾病相关的血栓形成。重组FVIIa已被开发为一种有效的止血药物,用于治疗有抑制性抗体的血友病患者。此外,它还用于对传统治疗无反应的出血患者。然而,重组FVIIa恢复止血的机制尚未明确界定。总之,TF:FVIIa复合物对止血至关重要,重组FVIIa是一种有效的止血药物。